Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.

Lorch A, Kleinhans A, Kramar A, Kollmannsberger CK, Hartmann JT, Bokemeyer C, Rick O, Beyer J.

J Clin Oncol. 2012 Mar 10;30(8):800-5. doi: 10.1200/JCO.2011.38.6391. Epub 2012 Jan 30.

2.

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O; German Testicular Cancer Study Group.

J Clin Oncol. 2007 Jul 1;25(19):2778-84.

PMID:
17602082
3.

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.

Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C; German Testicular Cancer Study Group.

J Clin Oncol. 2003 Nov 15;21(22):4083-91. Epub 2003 Oct 20.

PMID:
14568987
4.

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer J.

J Clin Oncol. 2011 Jun 1;29(16):2178-84. doi: 10.1200/JCO.2010.32.6678. Epub 2011 Mar 28.

PMID:
21444870
5.

Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features.

De Giorgi U, Rosti G, Salvioni R, Papiani G, Ballardini M, Pizzocaro G, Marangolo M.

Urol Oncol. 2011 May-Jun;29(3):284-90. doi: 10.1016/j.urolonc.2009.03.030. Epub 2009 Jun 24.

PMID:
19556152
6.

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.

Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC.

J Natl Cancer Inst. 2010 Aug 18;102(16):1253-62. doi: 10.1093/jnci/djq245. Epub 2010 Jul 14.

PMID:
20631341
7.

Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.

Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C; German Testicular Cancer Study Group.

J Clin Oncol. 2007 Dec 20;25(36):5742-7.

PMID:
18089869
8.

High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.

Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, Raggi D, Farè E, Magni M, Piva L, Matteucci P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM.

Ann Oncol. 2015 Jan;26(1):167-72. doi: 10.1093/annonc/mdu485. Epub 2014 Oct 24.

PMID:
25344361
9.

High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.

Pico JL, Fadel E, Ibrahim A, Bourhis JH, Droz JP.

Bull Cancer. 1995;82 Suppl 1:56s-60s. Review.

PMID:
7542945
10.
11.

Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.

Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, Lazarus HM, Einhorn LH.

Cancer. 1994 Mar 15;73(6):1716-20.

12.

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).

Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Ståhl E, Cohn-Cedermark G.

Acta Oncol. 2012 Feb;51(2):168-76. doi: 10.3109/0284186X.2011.641507. Epub 2011 Dec 19.

PMID:
22175254
13.

Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.

Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L, Deluca J, Budnick A, Ishill N, Mazumdar M, Bosl GJ, Motzer RJ.

J Clin Oncol. 2007 Jan 1;25(1):85-90. Erratum in: J Clin Oncol. 2007 May 20;25(15):2149.

PMID:
17194908
14.

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Fléchon A, Geoffrois L, Caty A, Soares DG, de Revel T, Fizazi K, Gligorov J, Micléa JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP.

Ann Oncol. 2014 Sep;25(9):1775-82. doi: 10.1093/annonc/mdu198. Epub 2014 Jun 3.

PMID:
24894084
15.

Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor.

Miki T, Mizutani Y, Akaza H, Ozono S, Tsukamoto T, Terachi T, Naito K, Nonomura N, Hara I, Yoshida O; Japan Blood Cell Transplantation Study Group for Testicular Germ Cell Tumor.

Int J Urol. 2007 Jan;14(1):54-9.

16.

High-dose chemotherapy in germ cell tumours: a large single centre experience.

Rick O, Beyer J, Kingreen D, Schwella N, Krusch A, Schleicher J, Kirsch A, Huhn D, Siegert W.

Eur J Cancer. 1998 Nov;34(12):1883-8.

PMID:
10023310
17.

A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.

Horwich A, Oliver RT, Wilkinson PM, Mead GM, Harland SJ, Cullen MH, Roberts JT, Fossa SD, Dearnaley DP, Lallemand E, Stenning SP; MRC Testicular Tumour Working Party.

Br J Cancer. 2000 Dec;83(12):1623-9.

18.

Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.

Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W.

Cancer. 1997 Jan 1;79(1):161-8.

PMID:
8988741
19.

A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.

Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G; Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.

J Natl Cancer Inst. 2008 Apr 16;100(8):533-41. doi: 10.1093/jnci/djn088. Epub 2008 Apr 8.

PMID:
18398095
20.

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ.

J Clin Oncol. 2007 Jan 20;25(3):247-56.

PMID:
17235042

Supplemental Content

Support Center